FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2008192281> ?p ?o ?g. }

• W2008192281 endingPage "439.e10" @default.
• W2008192281 startingPage "439.e1" @default.
• W2008192281 abstract "Background A new aqueous gel formulation of dapsone has been developed that allows clinically-effective doses of dapsone to be administered topically with minimal systemic absorption. Objectives The goal of these studies was to evaluate the efficacy and safety of dapsone gel, 5% in the treatment of acne. Methods Patients 12 years of age and older with acne vulgaris (N = 3010) participated in two identically-designed 12-week, randomized, double-blind studies of twice-daily monotherapy with dapsone gel, 5%, versus a vehicle gel. Results Dapsone gel–treated patients achieved superior results in terms of the investigator's global acne assessment (P < .001) and the mean percentage reduction in inflammatory, noninflammatory, and total lesion counts (all, P < .001) at week 12. Reductions in inflammatory lesion counts favoring dapsone gel over vehicle were apparent as early as 2 weeks and reached statistical significance by 4 weeks. No clinically significant changes in laboratory parameters, including hemoglobin, even among glucose-6-phosphate dehydrogenase–deficient patients, were observed. Adverse events were comparable between the treatment groups and rarely led to discontinuation. Limitations Adjunctive topical treatments and their impact on acne were not studied in this trial. Conclusions Dapsone gel, 5% appears to be an effective, safe, and well-tolerated treatment for acne vulgaris, with a rapid onset of action. A new aqueous gel formulation of dapsone has been developed that allows clinically-effective doses of dapsone to be administered topically with minimal systemic absorption. The goal of these studies was to evaluate the efficacy and safety of dapsone gel, 5% in the treatment of acne. Patients 12 years of age and older with acne vulgaris (N = 3010) participated in two identically-designed 12-week, randomized, double-blind studies of twice-daily monotherapy with dapsone gel, 5%, versus a vehicle gel. Dapsone gel–treated patients achieved superior results in terms of the investigator's global acne assessment (P < .001) and the mean percentage reduction in inflammatory, noninflammatory, and total lesion counts (all, P < .001) at week 12. Reductions in inflammatory lesion counts favoring dapsone gel over vehicle were apparent as early as 2 weeks and reached statistical significance by 4 weeks. No clinically significant changes in laboratory parameters, including hemoglobin, even among glucose-6-phosphate dehydrogenase–deficient patients, were observed. Adverse events were comparable between the treatment groups and rarely led to discontinuation. Adjunctive topical treatments and their impact on acne were not studied in this trial. Dapsone gel, 5% appears to be an effective, safe, and well-tolerated treatment for acne vulgaris, with a rapid onset of action." @default.
• W2008192281 created "2016-06-24" @default.
• W2008192281 creator A5009654209 @default.
• W2008192281 creator A5021906179 @default.
• W2008192281 creator A5023817287 @default.
• W2008192281 creator A5025545596 @default.
• W2008192281 creator A5039131845 @default.
• W2008192281 creator A5040567253 @default.
• W2008192281 creator A5069977428 @default.
• W2008192281 date "2007-03-01" @default.
• W2008192281 modified "2023-10-01" @default.
• W2008192281 title "Two randomized studies demonstrate the efficacy and safety of dapsone gel, 5% for the treatment of acne vulgaris" @default.
• W2008192281 cites W1985317924 @default.
• W2008192281 cites W1987103875 @default.
• W2008192281 cites W1993404332 @default.
• W2008192281 cites W2012798003 @default.
• W2008192281 cites W2021042136 @default.
• W2008192281 cites W2055895292 @default.
• W2008192281 cites W2058883756 @default.
• W2008192281 cites W2071240873 @default.
• W2008192281 cites W2088220515 @default.
• W2008192281 cites W2106864539 @default.
• W2008192281 cites W2108519992 @default.
• W2008192281 cites W2134002686 @default.
• W2008192281 doi "https://doi.org/10.1016/j.jaad.2006.10.005" @default.
• W2008192281 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/17208334" @default.
• W2008192281 hasPublicationYear "2007" @default.
• W2008192281 type Work @default.
• W2008192281 sameAs 2008192281 @default.
• W2008192281 citedByCount "98" @default.
• W2008192281 countsByYear W20081922812012 @default.
• W2008192281 countsByYear W20081922812013 @default.
• W2008192281 countsByYear W20081922812014 @default.
• W2008192281 countsByYear W20081922812015 @default.
• W2008192281 countsByYear W20081922812016 @default.
• W2008192281 countsByYear W20081922812017 @default.
• W2008192281 countsByYear W20081922812018 @default.
• W2008192281 countsByYear W20081922812019 @default.
• W2008192281 countsByYear W20081922812021 @default.
• W2008192281 countsByYear W20081922812022 @default.
• W2008192281 countsByYear W20081922812023 @default.
• W2008192281 crossrefType "journal-article" @default.
• W2008192281 hasAuthorship W2008192281A5009654209 @default.
• W2008192281 hasAuthorship W2008192281A5021906179 @default.
• W2008192281 hasAuthorship W2008192281A5023817287 @default.
• W2008192281 hasAuthorship W2008192281A5025545596 @default.
• W2008192281 hasAuthorship W2008192281A5039131845 @default.
• W2008192281 hasAuthorship W2008192281A5040567253 @default.
• W2008192281 hasAuthorship W2008192281A5069977428 @default.
• W2008192281 hasConcept C141071460 @default.
• W2008192281 hasConcept C16005928 @default.
• W2008192281 hasConcept C197934379 @default.
• W2008192281 hasConcept C2777640609 @default.
• W2008192281 hasConcept C2777673923 @default.
• W2008192281 hasConcept C2778715236 @default.
• W2008192281 hasConcept C71924100 @default.
• W2008192281 hasConcept C98274493 @default.
• W2008192281 hasConceptScore W2008192281C141071460 @default.
• W2008192281 hasConceptScore W2008192281C16005928 @default.
• W2008192281 hasConceptScore W2008192281C197934379 @default.
• W2008192281 hasConceptScore W2008192281C2777640609 @default.
• W2008192281 hasConceptScore W2008192281C2777673923 @default.
• W2008192281 hasConceptScore W2008192281C2778715236 @default.
• W2008192281 hasConceptScore W2008192281C71924100 @default.
• W2008192281 hasConceptScore W2008192281C98274493 @default.
• W2008192281 hasIssue "3" @default.
• W2008192281 hasLocation W20081922811 @default.
• W2008192281 hasLocation W20081922812 @default.
• W2008192281 hasOpenAccess W2008192281 @default.
• W2008192281 hasPrimaryLocation W20081922811 @default.
• W2008192281 hasRelatedWork W1548690167 @default.
• W2008192281 hasRelatedWork W1794769932 @default.
• W2008192281 hasRelatedWork W1994508586 @default.
• W2008192281 hasRelatedWork W2019073926 @default.
• W2008192281 hasRelatedWork W2068321231 @default.
• W2008192281 hasRelatedWork W241389296 @default.
• W2008192281 hasRelatedWork W2567015835 @default.
• W2008192281 hasRelatedWork W4210853480 @default.
• W2008192281 hasRelatedWork W4232979455 @default.
• W2008192281 hasRelatedWork W65571214 @default.
• W2008192281 hasVolume "56" @default.
• W2008192281 isParatext "false" @default.
• W2008192281 isRetracted "false" @default.
• W2008192281 magId "2008192281" @default.
• W2008192281 workType "article" @default.